Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"so I covered"
Seems like early morning sentiment changed by afternoon...? that type of swinging mindset should give all pause for any seriousness in posts
I think it's real hard to draw any conclusions considering the source has been so consistently wrong...
Here I will fix this for you:
"Stock holding up well today. The large seller is finished."
Probably should have just left the original correct version before it was made incorrect.
Ouch. Bad move. I'll bet covering will happen before "a dime"
Too bad this move backfired. Poor choice, poor timing.
I saw your trade come through. You might not have seen the purchase because rather than marking the order AON, it was submitted FOS
It can't be both a paint job and down 23 percent. Maybe the shorts don't do as much DD as claimed...
I think a ihub shareholder meeting regarding IPIX is a great idea. How wonderful it would be to meet face to face. I could probably invite a small army of assertive shareholders who could discuss effective ways to suppress the misinformation spread about this company. We could refer to it a Judgement Day. Keep me posted for the details.
I'm reading threw this post and trying to find the worthy content...can you please point me to anything of value...maybe re-write? Seems like a pattern with the meaningless posts...
Thank you for this! Nice to have a trustworthy shareholder in contact with Leo.
Thanks for this explanation. This is the piece I was missing from following your logic.
Thanks for your contributions to the discussion.
Thanks for giving me some good reading materials. I will take a thorough look at what you provided. In the meantime, what has stood out for me already is: "A sponsor may transfer responsibility for any or all of the obligations set forth in this part to a contract research organization."
Relentless,
Yes, I do! Thanks for the reminder. Now I will be your best friend if you can find it for me! LOL
Thanks for talking to your experience.
Unless something has changed, I do not think sponsor has CRF access until after the trial has finished.
Upon completion of the 2a trail, March 1st 2016. "As the trial is a randomized, double-blind design with a placebo arm, we, nor anyone, can speculate on the outcome until all data is collected, un-blinded and analyzed." commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "
Hi Yooper61, Thanks for this analysis. You state "Since mgmt gets the Case Report Forms (CRFs)", which I believe to be true, but the only thing I CAN'T verify is WHEN.
My assumption is management gets to see the CRFs after the trial is finished and unblinded, not before. If I missed that in your links, can you point it out to me? Or is there another document that talks about trial sponsors seeing CRFs BEFORE the trial is complete? Thanks!
With all those huge winners, how come you only post on this board?
People tend to only speak about their winners, not their losers. I'm sure your doing just fine
Investing in biopharma isn't for everyone and requires more patience than a fruitfly. Good luck with your trading.
Aw, shucks. Might have to move along to another stock to trade... :(
And just to add one more ounce of confidence...."Pharmacokinetic data further revealed an early and dose-dependent response that improved as treatment duration increased. "
PK data supports the trial results...can't fudge the PK....
Thanks, bud!
Were you able to accumulate all the shares you intended with this inaccurate post?
HMMMMM..... Let's reflect for a minute....
Leo has said on 1/16 "In coming weeks, we look forward to advancing these discussions with attractive partnership/licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders." Guess what folks, we are "in coming weeks".
Also, if anyone has been doing their homework on P. We are well past the database soft lock...and are within a week or 2 of topline data. A drug that we know Leo wants to partner....
Both of these things are going on concurrently...but
Now all of a sudden cash is a immediate concern? Leo has been running the company with about $3 million to spare for the last 9 months, but now, today, it's not okay. Just when we are about to determine the "best path forward"...
He's got plenty left under Aspire. Leo has gotten private investors to put a couple million down. Then, there is the shelf...
So our CEO, is a CPA with tons of finance experience as has been keeping this operation going for years...
I tell you the one thing that doesn't make sense to me...all the focus on immediate need for cash
Sorry for your loss, KarinCA. My thoughts to you and your family.
You will have all of your answers in short order. I was just providing you with a means to get answers sooner.
You should try emailing Leo directly for your inquiries. He is very responsive to shareholders.
If we get no early surprises, I am focused on the end of February. I was looking at the dates/timeline for P 2a and trying to use those as a benchmark for a timeline for the P 2b. At this point, the database soft lock should already be complete. And if the timeline for results is the same as the 2a, the 2b results should be released 2/23/18. So that puts us about 1 month out. For sure, there will be a run up starting soon in anticipation for that result.
But, then we will also be getting closer to learning the status of B-OM Breakthrough Designation. I think Leo is going to partner B-OM once he learns the status of that application as it will surely give him clarity on the size of the phase 3 for B-OM and therefore IPIX and partner will be able to estimate the cost.
Large fake asks like that are usually seen when someone is trying to accumulate shares. Magically this on disappeared
Hmmmmm....
Maybe you haven't been following, but he has the B-OM. Good luck to you.
You had better email Leo and let him know our expectations...
HMMMMMMMMMMMMMMMMM.......
Leo could have dropped the secondary endpoint data on January 8th during the presentation, but alas, he PRs it on the Wednesday before...
Leo could have released the corporate presentation during the 4pm PST timeslot and linked us to a webcast, but instead we get the presentation 5 days before the meeting and no link to the webcast...
So we get information early and then radio silence during the Showcase and afterwards...
HMMMMMMMMMMMMMMMMM.......
November 16th - "Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results."
November 16th PR
December 11th -"We are waiting now for secondary study endpoints."
207331
January 3rd - "The delay of onset of SOM data further support the positive primary endpoint findings that showed a clear reduction in the incidence of SOM in patients receiving Brilacidin-OM treatment."
January 3rd PR
January 8-10th. "Showcase your company to life science investors and strategic partners during the industry’s most important annual gathering."
Biotech Showcase
February 15.
NITE 0.7477 1,800 13:23
ETRF 0.7477 1,000 13:13
CSTI 0.7477 1,000 13:22
Three different sellers or collusion?
Could very well be the case. Probably the same company that suggested to Leo to forgo the interim data.
If the company's goal is to partner P after this 2b trial, there is no need for interim data. As we see with B-OM, companies want final results before inking the deal.
Leo suggested that if he would have done the interim analysis, it would have potentially required more patients to account for some investigator bias, which would have made the trial take longer. I'm sure he wants to take the quickest path to a deal.
Well done, sir. Well done.
Plenty, thanks for this information and for giving us all some new perspective on B-OM relating to other trials.
I have a question though, because I'm not sure I see the connection between sachets and how it relates to mucoadhesive buccal tablet. When I read the IPIX PR, it reads more from the perspective of manufacturing and ease of use for patients which is why the company is considering sachets. The image I got was patients will get a box with dozens of packets (like packets of sugar) that they could mix into water to perform the swish and spit.
Also, when I go back to Cabel's conversation with Leo, I see...
"Will you try to increase doage(sic) or frequency of dosage,..? Why would I want to do this? I would believe the FDA would be encouraging us to move forward towards approval with these results. ". To me, this doesn't read like he's looking for increased contact time, etc...
So how do you get to "improving Brilacidin contact time with sachets"?
If you could help me see the missing dots I would appreciate it. Thanks.